Posted by Michael Wonder on 29 Apr 2016
Therabron Therapeutics receives FDA fast track designation for rhCC10 for the prevention of chronic lung disease related to premature birth
28 April 2016 - Therabron Therapeutics announced today that it has received Fast Track Designation from the U.S. FDA for rhCC10 (recombinant human Club Cell 10 kDa Protein), specifically for the prevention of chronic lung disease related to premature birth.
Therabron Therapeutics’ lead biopharmaceutical product candidate is a proprietary preparation of recombinant human CC10 protein which has potential clinical applications, based on its potent anti-inflammatory properties, in a variety of respiratory diseases. CG100, the company’s lead compound based on rhCC10 and intended to prevent chronic lung disease in neonates, is currently in a Phase 2 clinical trial enrolling 88 preterm infants. This ongoing Phase 2 study is supported, in part, by a grant from the U.S. FDA Office of Orphan Product Development.
For more details, go to: http://therabron.com/wp-content/uploads/2016/04/Press-release-Therabron-Fast-Track-Designation-FINAL-428.pdf
